GlassScriptPhysician profile
James M Graham
NPI 1437448594
$7,757.59
in general payments reported to CMS, 2019-2025
27 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $355 · 2021: $484 · 2022: $917 · 2023: $1,174 · 2024: $1,903 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,513 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,512.98 |
| Education | $193.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,270.03 | 2019-2025 | |
| Lilly USA, LLC | $1,263.62 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $922.74 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $742.13 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $625.52 | 2019-2025 | Tremfya |
| Ucb, INC. | $490.43 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $415.29 | 2019-2025 | |
| Leo Pharma INC. | $409.99 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $369.97 | 2019-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $324.83 | 2022-2025 | Sotyktu |
| Incyte Corporation | $248.90 | 2021-2024 | Opzelura |
| Genzyme Corporation | $158.59 | 2019-2025 | |
| Amgen INC. | $87.30 | 2019-2023 | Otezla |
| Dermavant Sciences, INC. | $66.73 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $42.30 | 2021-2025 | Nemluvio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $41.91 | 2025 | Vtama |
| Kerecis Limited | $41.76 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.32 | 2023-2024 | Spevigo |
| Allergan, INC. | $37.55 | 2021 | |
| Genentech USA, INC. | $26.85 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $26.82 | 2023-2025 | Zoryve |
| Dermira, INC. | $20.62 | 2020 | |
| Sensus Healthcare, INC. | $17.79 | 2019 | |
| Celgene Corporation | $17.08 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.02 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.72 | 2023 | Arazlo |
| Elekta, INC. | $14.78 | 2025 | Flexitron Hdr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.